Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Alexander Fefer"'
Publikováno v:
Bone Marrow Transplantation. 19:867-873
Interleukin-12 (IL-12) has been reported to enhance the cytolytic activity of NK and activated T cells and to induce low levels of lymphokine-activated killer (LAK) activity in normal human lymphocytes. Therapy with IL-12 has induced tumor eradicatio
Autor:
Catherine G. Lindgren, Alexander Fefer, Ted Yednock, Nicholas L. Kovach, John A. Thompson, John M. Harlan
Publikováno v:
Blood. 84:2234-2242
Peripheral blood lymphocytes (PBLs) cultured in the presence of recombinant human interleukin-2 (rhIL-2) develop a natural killer (NK) cell phenotype (CD16+, CD56+, CD3-) and are referred to as lymphokine- activated killer cells (LAK). In developing
Autor:
Alexander Fefer, Ted Gooley, Stephen H. Petersdorf, Edus H. Warren, Frederick R. Appelbaum, Yoshihiro Inamoto, Brenda M. Sandmaier, Jean E. Sanders, Paul J. Martin, Mary E.D. Flowers, Rainer Storb
The efficacy of donor lymphocyte infusion (DLI) for treatment of relapsed acute leukemia after allogeneic hematopoietic cell transplantation is limited. We hypothesized that interleukin-2 (IL-2) combined with DLI after chemotherapy might augment graf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbf925256b8035284ec3641fe6febda3
https://europepmc.org/articles/PMC3123407/
https://europepmc.org/articles/PMC3123407/
Publikováno v:
Journal of Immunotherapy. 14:322-328
Optimal conditions for expanding tumor-infiltrating lymphocytes (TILs) specifically cytotoxic for autologous melanoma for clinical use have not yet been identified. In several small studies, interleukin (IL)-4 was reported to promote the growth of su
Publikováno v:
Journal of Immunotherapy. 13:208-212
Seventy patients consecutively admitted to a single institution were treated with high-dose interleukin-2 (IL-2) and analyzed for determining the incidence and risk factors associated with reactions to i.v. contrast media. Patients with metastatic re
Autor:
M C Benyunes, Catherine G. Lindgren, James A. Bianco, John A. Thompson, Anthony F. Shields, Alexander Fefer
Publikováno v:
Journal of Immunotherapy. 13:84-90
Pentoxifylline (PTX) is a methylated xanthine that has been shown to reduce the toxicity of Interleukin-2 (IL-2) therapy in animal models, possibly by inhibiting secretion of tumor necrosis factor-alpha. However, the use of PTX to reduce IL-2 toxicit
Autor:
M C Benyunes, Alexander Fefer, John A. Thompson, A York, C. Massumoto, Catherine G. Lindgren, C. Higuchi, C. D. Buckner
Publikováno v:
Acta Haematologica. 89:2-7
Patients who undergo autologous bone marrow transplantation (ABMT) for advanced hematologic malignancies experience a high relapse rate. Therapy with interleukin-2 (IL-2) +/- lymphokine-activated killer (LAK) cells has induced clinical responses in s
Autor:
Paul H. Lange, Alexander Fefer, John A. Thompson, William H. Bush, Cathy G. Lindgren, M C Benyunes, Keith L. Shulman, Lynn A. Benz, Carolyn Collins
Publikováno v:
Journal of Clinical Oncology. 10:960-968
PURPOSE Two consecutive protocols of continuous intravenous (CIV) infusion interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells were carried out in patients with metastatic renal cell carcinoma (RCC) to determine the response rate and tox
Publikováno v:
Blood. 77:2561-2568
Autologous bone marrow transplantation (ABMT) for advanced hematologic malignancies is associated with high relapse rates. Interleukin-2 (IL- 2) and lymphokine-activated killer (LAK) cells represent a potentially non-cross-resistant therapeutic modal
Autor:
John A. Thompson, Stephen J. Forman, Oliver W. Press, Alexander Fefer, Joseph M. Unger, Michael LeBlanc, Patrick J. Stiff, Auayporn Nademanee, Stephen H. Petersdorf, Richard I. Fisher
Publikováno v:
Blood. 111(8)
To determine the effect of posttransplantation immunotherapy with IL-2 on the progression-free survival (PFS) and overall survival (OS) of patients with non-Hodgkin lymphoma (NHL) after autologous stem-cell transplantation (PBSCT), patients with prev